Gladstone Institutional Advisory LLC Acquires Shares of 9,859 TransMedics Group, Inc. (NASDAQ:TMDX)

Gladstone Institutional Advisory LLC purchased a new stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 9,859 shares of the company's stock, valued at approximately $615,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its position in TransMedics Group by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 763,790 shares of the company's stock valued at $119,938,000 after acquiring an additional 10,106 shares during the period. Allspring Global Investments Holdings LLC increased its position in TransMedics Group by 5.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company's stock valued at $94,061,000 after acquiring an additional 30,092 shares during the period. Vaughan Nelson Investment Management L.P. increased its position in TransMedics Group by 9.9% in the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company's stock valued at $22,547,000 after acquiring an additional 32,605 shares during the period. Charles Schwab Investment Management Inc. increased its position in TransMedics Group by 2.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company's stock valued at $42,656,000 after acquiring an additional 6,634 shares during the period. Finally, Principal Financial Group Inc. increased its position in TransMedics Group by 260.1% in the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company's stock valued at $31,759,000 after acquiring an additional 146,115 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of the firm's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the transaction, the insider now directly owns 20,843 shares of the company's stock, valued at approximately $1,800,835.20. This trade represents a 4.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 7.00% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on TMDX. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a research report on Wednesday, February 5th. TD Cowen decreased their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a "buy" rating for the company in a research report on Monday, November 18th. Piper Sandler decreased their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an "overweight" rating for the company in a research report on Wednesday, December 11th. Oppenheimer reiterated an "outperform" rating and set a $125.00 price objective on shares of TransMedics Group in a research report on Tuesday, December 3rd. Finally, JPMorgan Chase & Co. reiterated a "neutral" rating and set a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, TransMedics Group presently has a consensus rating of "Moderate Buy" and a consensus target price of $122.70.

TransMedics Group Stock Up 3.6 %

NASDAQ:TMDX traded up $2.57 during trading hours on Tuesday, reaching $74.75. The company had a trading volume of 558,591 shares, compared to its average volume of 2,239,738. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The firm has a market cap of $2.51 billion, a price-to-earnings ratio of 79.35 and a beta of 2.12. The business's 50-day simple moving average is $65.92 and its two-hundred day simple moving average is $105.97. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.